Now playing catch-up to bluebird, Vertex and CRISPR send in their pitch for blood disorder cell therapy
If all things go according to plan, the FDA could start reviewing the first-ever filing for a CRISPR therapy this November.
Vertex and CRISPR Therapeutics …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
